Your browser is no longer supported. Please, upgrade your browser.
Cerevel Therapeutics Holdings, Inc.
Index- P/E- EPS (ttm)-2.41 Insider Own0.10% Shs Outstand127.23M Perf Week-0.30%
Market Cap1.78B Forward P/E- EPS next Y-1.71 Insider Trans0.00% Shs Float99.99M Perf Month-2.48%
Income-199.20M PEG- EPS next Q-0.39 Inst Own78.90% Short Float4.23% Perf Quarter-15.21%
Sales- P/S- EPS this Y20.40% Inst Trans3.30% Short Ratio17.68 Perf Half Y-17.05%
Book/sh2.67 P/B5.01 EPS next Y-6.90% ROA-69.00% Target Price22.00 Perf Year-
Cash/sh2.59 P/C5.17 EPS next 5Y- ROE-78.70% 52W Range9.00 - 18.83 Perf YTD-19.30%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-28.96% Beta-
Dividend %- Quick Ratio10.20 Sales past 5Y- Gross Margin- 52W Low48.67% ATR0.85
Employees104 Current Ratio10.20 Sales Q/Q- Oper. Margin- RSI (14)45.45 Volatility5.68% 6.26%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.82 Prev Close13.93
ShortableYes LT Debt/Eq0.00 EarningsMay 17 BMO Payout- Avg Volume239.27K Price13.38
Recom1.30 SMA20-2.46% SMA50-4.68% SMA200-0.35% Volume195,678 Change-3.95%
Dec-10-20Initiated Goldman Buy $24
Nov-23-20Initiated Jefferies Buy $18
Nov-09-20Initiated Stifel Buy $17
May-27-21 07:00AM  
May-17-21 06:30AM  
May-04-21 07:00AM  
Apr-29-21 07:00AM  
Apr-21-21 07:00AM  
Apr-13-21 06:30AM  
Mar-24-21 06:30AM  
Mar-22-21 07:00AM  
Feb-24-21 07:00AM  
Jan-29-21 12:14AM  
Jan-28-21 07:00AM  
Jan-21-21 07:00AM  
Dec-18-20 06:11AM  
Dec-14-20 07:00AM  
Dec-08-20 07:00AM  
Dec-04-20 07:00AM  
Nov-23-20 07:00AM  
Nov-16-20 06:30AM  
Nov-04-20 07:00AM  
Oct-30-20 07:00AM  
May-15-20 07:09AM  
Apr-08-20 07:00AM  
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing CVL-231, a positive allosteric modulator (PAM) that is in Phase Ib clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase II proof-of-concept trials in drug-resistant focal onset seizures in epilepsy or focal onset epilepsy, as well as Phase I proof-of-principle trial for acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in Phase III clinical trials for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist for the treatment of dementia-related apathy; and CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I single ascending dose trials for the treatment of substance use disorder. It is also involved in the development of various preclinical portfolio for various neuroscience indications. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MISHAN ORLYChief Business OfficerJan 26Option Exercise3.5038,450134,57538,450Jan 28 07:35 PM
BAIN CAPITAL INVESTORS LLC10% OwnerNov 09Buy10.30332,2933,422,61860,632,356Nov 12 05:54 PM
Koppel AdamDirectorNov 09Buy10.30332,2933,422,61860,632,356Nov 12 05:54 PM
Gordon Christopher RDirectorNov 09Buy10.30332,2933,422,61860,632,356Nov 12 05:51 PM